A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.
Also called NCT06972732
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 204 participants
- Registry
-
NCT06972732
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06972732. Randomized; no masking; primary purpose treatment. Start 2025-06-11 (actual); primary completion 2026-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
- Acronym
- TELOS
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Dapagliflozin/Pioglitazone
- Intervention (Drug)
- Dapagliflozin/Sitagliptin
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct06972732- Content hash
39df9c773cc1af3fe1d27b38c3cd1457db781d25c1a71ceaff092ca40b06a8ca